| Revenue growth | Q2 +25%, H1 +26% YoY, broad-based across categories and geographies |
|---|---|
| Margins | Q2 EBITDA margin 33.8% (-200 bps); ex-injectable/Stellon 37.1% |
| Demand visibility | Wallet share gains; advanced discussions with large customers |
| Management confidence | Confident of sustainable long-term growth; no numeric targets |
Growth
Q2 EBITDA ₹104.4 Cr (+18%), margin 33.8% (-200 bps). H1 EBITDA ₹186.8 Cr (+25%), PAT ₹127.3 Cr (+19%).
Outlook
No numeric guidance given; targets 2-3 product launches yearly. 1:1 bonus issue approved.
Risks
Gross margin down 400 bps in Q2 on input costs and product mix; formulations revenue down 8% in H1.
Last quarter's promises, checked
Partly delivered
- Sustain ~26% growth momentum → Q2 +25%, H1 +26% (= PARTIAL: in line, no beat)
- 2-3 product launches yearly → Inspira dermatology launched; count not disclosed (= PARTIAL)
Missed
- EBITDA margin to beat sales growth, moving toward 40% → Q2 margin 33.8% (-200 bps), EBITDA +18% vs revenue +25% (= MISS)
- Domestic formulations double-digit growth ex-Middle East → Q2 formulations +6%, H1 -8% (= MISS)
- Sustain historical margins as injectables ramp → Q2 gross margin -400 bps on input costs and mix (= MISS)
Investor Presentation filed with BSE, NSE: CONCORDBIO. Summary written with AI assistance from the document.
Concord Biotech Ltd: key numbers
- Share price
- ₹1,265.60
- Market cap
- ₹13,240 Cr
- Revenue (annual)
- ₹1,055 Cr
- Net profit (annual)
- ₹260.9 Cr
- P/E (TTM)
- 46.9×Sector 46.5×
- Promoter holding
- 44.09%+0.01% QoQ
- FII holding
- 7.28%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Concord Biotech Ltd
All →Concord Biotech Earnings Call Transcript: Key Takeaways
Revenue grew 25% YoY driven by API demand, but gross margins contracted 400bps due to rising solvent costs and geopolitical disruptions.
- Call
- Guides 18% growth
Concord Biotech Bonus Issue
Concord Biotech fixed 4 November 2026 as the record date for a 1:1 bonus issue, with deemed allotment on 5 November 2026. The bonus is subject to statutory and regulatory approvals.
Concord Biotech Q2 FY27 Results: Net Profit ₹69.6 Cr, Up 10.3% YoY
Concord Biotech Ltd reported revenue from operations of ₹309.1 Cr (+25.1% YoY) and net profit of ₹69.6 Cr (+10.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹69.6 Cr · +10.3% YoY
Concord Biotech Bonus Issue
Concord Biotech's postal ballot approved a bonus issue and an authorised capital increase. No cash is paid and no ratio is stated.
Concord Biotech Board Meeting Date
Concord Biotech has scheduled its Q2 FY27 board meeting for 27 Oct 2026 to approve standalone and consolidated results. Trading window remains closed until 48 hours post result declaration.
Concord Biotech Other Announcement
Concord Biotech Ltd has filed its quarterly shareholding pattern under Regulation 31 for the period ended September 30, 2026.